february 1866

Ivermectin is an antiparasitic drug, and a very good one. If you are infected with the roundworms that cause river blindness or the parasitic mites that cause scabies, it is wonderfully effective. It is cheap; it is accessible; and its discoverers won the Nobel Prize in 2015. It has also been widely promoted as a coronavirus prophylactic and treatment.

This promotion has been broadly criticized as a fever dream conceived in the memetic bowels of the internet and as a convenient buttress for bad arguments against vaccination. This is not entirely fair. Perhaps 70 to 100 studies have been conducted on the use of ivermectin for treating or preventing COVID-19; several dozen of them support the hypothesis that the drug is a plague mitigant. Two meta-analyses, which looked at data aggregated across subsets of these studies, concluded that the drug has value in the fight against the pandemic.

If you were to look under the roofs of American homes at random, it wouldn’t take long to find someone who lives alone. By the Census Bureau’s latest count, there are about 36 million solo dwellers, and together they make up 28 percent of U.S. households.

Even though this percentage has been climbing steadily for decades, these people are still living in a society that is tilted against them. In the domains of work, housing, shopping, and health care, much of American life is a little—and in some cases, a lot—easier if you have a partner or live with family members or housemates. The number of people who are inconvenienced by that fact grows every year.

Those who live alone, to be clear, are not lonely and miserable. Research indicates that, young or old, single people are more social than their partnered peers. Bella DePaulo, the author of How We Live Now: Redefining Home and Family in the 21st Century, reeled off to me some of the pleasures of having your own space: “the privacy, the freedom to arrange your life and your space just the way you want it—you get to decide when to sleep, when to get up, what you eat, when you eat, what you watch on Netflix, how you set the thermostat.”

Many years ago, when I was a junior professor at Yale, I cold-called a colleague in the anthropology department for assistance with a project I was working on. I didn’t know anything about the guy; I just selected him because he was young, and therefore, I figured, more likely to agree to talk.

Five minutes into our lunch, I realized that I was in the presence of a genius. Not an extremely intelligent person—a genius. There’s a qualitative difference. The individual across the table seemed to belong to a different order of being from me, like a visitor from a higher dimension. I had never experienced anything like it before. I quickly went from trying to keep up with him, to hanging on for dear life, to simply sitting there in wonder.

The U.S. economy right now is a little bit like Dune.

Not Frank Herbert’s magisterial sci-fi epic novel, or Denis Villeneuve’s new and reportedly sumptuous film adaptation. I mean David Lynch’s infamously bewildering 1984 movie version, which is remembered mostly for being a semi-glorious mess. Like that space oddity, today’s economy is too strange to neatly categorize as “clearly great” or “obviously terrible.” You keep waiting for it to just be normal. But it stays weird—big economic indicators point in conflicting directions—so you have to accept that nothing is going to make sense for a while, and maybe it’ll be okay.

Americans are buying more stuff than ever before. That’s good. But because of supply constraints, it can feel like there’s a painful shortage of just about everything. That’s bad. Economic growth is booming, but the president’s approval rating on the economy is falling, which is a historically odd juxtaposition. Businesses everywhere are struggling to fill jobs, which sounds bad, but employer pain is workers’ gain, and wages are rising, which is wonderful. But because prices are rising too, inflation-adjusted hourly-wage growth actually declined in September, which is not wonderful.

In the spring of 2020, as Boston’s first COVID-19 wave raged, I was the gastroenterologist on call responding to a patient hospitalized with a stomach ulcer. Wearing a layer of yellow personal protective equipment over a pair of baggy scrubs, I spent 30 minutes explaining to him that he needed an endoscopic procedure. We built a rapport, and by the end of our conversation about the pros and cons, he seemed to agree with my recommendation. I told him we would be ready to perform his endoscopy within half an hour.

“Well, before we do anything, I’m going to need to discuss it with the doctor.”

I blinked.

When I entered the room, I had introduced myself as the doctor. I had also just explained, in great detail, a highly specialized procedure.